{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:07:56Z","timestamp":1789128476568,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ahram Canadian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rift valley fever virus (RVFV) is among the WHO list of priority diseases, yet no effective vaccine or treatment is currently available. Microbial pigments (MPs) represent a promising small-molecules library which can be exploited for the drug discovery of anti-RVFV compound. In this study, thirteen MPs were in silico screened to identify candidates with acceptable drug-likeness and possible ability to cross the blood brain barrier. Next, the binding interaction of the filtered molecules were compared against key RVFV proteins for the selection of the optimum inhibitor. Molecular dynamics simulations were performed (200 ns) to further evaluate the interactions. The selected candidate (pyocyanin; PCN) was produced, purified and analytically characterized in-house. Finally, the antiviral potential of PCN was tested in vitro against RVFV using the tissue culture infection dose 50% (TCID\n                    <jats:sub>50<\/jats:sub>\n                    ) method. In silico screening studies revealed that prodigiosin and PCN exhibit ideal drug-likeness properties. PCN exerted a promising in silico interaction with the key RVFV proteins as revealed by the molecular docking and dynamic studies. Results showed that PCN may be effectively produced and purified from bacterial cultures. Its cell-safe concentration (0.49 \u03bcg\/mL) demonstrated a promising 2.89 log\n                    <jats:sub>10<\/jats:sub>\n                    reduction in TCID\n                    <jats:sub>50<\/jats:sub>\n                    when incubated with RVFV infected cells. A lower effect was observed (2.00 log\n                    <jats:sub>10<\/jats:sub>\n                    reduction) in cells treated with PCN prior to RVFV infection. These results suggest that PCN may represent a potential effective low-cost molecule to combat RVFV.\n                  <\/jats:p>","DOI":"10.1186\/s13065-025-01680-2","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:19:19Z","timestamp":1770697159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microbial pigments as potential anti-rift valley fever virus drugs"],"prefix":"10.1186","volume":"20","author":[{"given":"Faten","family":"Farouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan M. E.","family":"Azzazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"20","key":"1680_CR1","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1056\/NEJMp2308666","volume":"389","author":"N Wandera","year":"2023","unstructured":"Wandera N, Olds P, Muhindo R, Ivers L. Rift valley fever\u2014the need for an integrated response. N Engl J Med. 2023;389(20):1829\u201332.","journal-title":"N Engl J Med"},{"key":"1680_CR2","first-page":"51","volume-title":"Rift valley fever","author":"JM Meegan","year":"2019","unstructured":"Meegan JM, Bailey CL. Rift valley fever. In The arboviruses: CRC Press; 2019. p. 51\u201376."},{"issue":"1","key":"1680_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/microorganisms13010091","volume":"13","author":"CM Muvunyi","year":"2025","unstructured":"Muvunyi CM, Ngabonziza JCS, Siddig EE, Ahmed A. Rift Valley fever in Rwanda is urging for enhancing global health security through multisectoral one health strategy. Microorganisms. 2025;13(1):91.","journal-title":"Microorganisms"},{"key":"1680_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.170302","volume":"917","author":"Z Wang","year":"2024","unstructured":"Wang Z, Pei S, Ye R, Chen J, Cheng N, Zhao M, et al. Increasing evolution, prevalence, and outbreaks for rift valley fever virus in the process of breaking geographical barriers. Sci Total Environ. 2024;917:170302.","journal-title":"Sci Total Environ"},{"issue":"8","key":"1680_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1099\/jgv.0.001296","volume":"100","author":"D Wright","year":"2019","unstructured":"Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley fever: biology and epidemiology. J Gen Virol. 2019;100(8):1187\u201399.","journal-title":"J Gen Virol"},{"key":"1680_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijidoh.2024.100035","volume":"4","author":"E Remera","year":"2024","unstructured":"Remera E, Rwagasore E, Muvunyi CM, Ahmed A. Emergence of the first molecularly confirmed outbreak of Rift Valley fever among humans in Rwanda, calls for institutionalizing the One Health strategy. IJID One Health. 2024;4:100035.","journal-title":"IJID One Health"},{"issue":"3","key":"1680_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010233","volume":"16","author":"Z Anywaine","year":"2022","unstructured":"Anywaine Z, Lule SA, Hansen C, Warimwe G, Elliott A. Clinical manifestations of Rift Valley fever in humans: systematic review and meta-analysis. PLoS Negl Trop Dis. 2022;16(3):e0010233.","journal-title":"PLoS Negl Trop Dis"},{"key":"1680_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102676","volume":"57","author":"J Salmanton-Garc\u00eda","year":"2024","unstructured":"Salmanton-Garc\u00eda J, Wipfler P, Leckler J, Naucl\u00e9r P, Mallon PW, Bruijning-Verhagen PCJL, et al. Predicting the next pandemic: VACCELERATE ranking of the World Health Organization\u2019s blueprint for action to prevent epidemics. Travel Med Infect Dis. 2024;57:102676.","journal-title":"Travel Med Infect Dis"},{"issue":"21","key":"1680_CR9","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/ajhp\/zxaa228","volume":"77","author":"OI Piatek","year":"2020","unstructured":"Piatek OI, Ning JC-M, Touchette DR. National drug shortages worsen during COVID-19 crisis: proposal for a comprehensive model to monitor and address critical drug shortages. Am J Health-Syst Pharm. 2020;77(21):1778\u201385.","journal-title":"Am J Health-Syst Pharm"},{"issue":"10","key":"1680_CR10","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","volume":"24","author":"V Parvathaneni","year":"2019","unstructured":"Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019;24(10):2076\u201385.","journal-title":"Drug Discov Today"},{"issue":"35","key":"1680_CR11","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1002\/ange.201404761","volume":"126","author":"K Nicolaou","year":"2014","unstructured":"Nicolaou K. Advancing the drug discovery and development process. Angew Chem. 2014;126(35):9280\u201392.","journal-title":"Angew Chem"},{"issue":"3","key":"1680_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2217\/fvl.09.1","volume":"4","author":"SK Saxena","year":"2009","unstructured":"Saxena SK, Mishra N, Saxena R. Advances in antiviral drug discovery and development: Part II: advancements in antiviral drug development. Future Virol. 2009;4(3):209\u201315.","journal-title":"Future Virol"},{"issue":"6","key":"1680_CR13","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1039\/D0CS01118E","volume":"50","author":"CS Adamson","year":"2021","unstructured":"Adamson CS, Chibale K, Goss RJM, Jaspars M, Newman DJ, Dorrington RA. Antiviral drug discovery: preparing for the next pandemic. Chem Soc Rev. 2021;50(6):3647\u201355.","journal-title":"Chem Soc Rev"},{"issue":"7","key":"1680_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","volume":"22","author":"A von Delft","year":"2023","unstructured":"von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, et al. Accelerating antiviral drug discovery: lessons from COVID-19. Nat Rev Drug Discov. 2023;22(7):585\u2013603.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1680_CR15","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1002\/ptr.7039","volume":"35","author":"SI Ali","year":"2021","unstructured":"Ali SI, Sheikh WM, Rather MA, Venkatesalu V, Muzamil Bashir S, Nabi SU. Medicinal plants: treasure for antiviral drug discovery. Phytother Res. 2021;35(7):3447\u201383.","journal-title":"Phytother Res"},{"issue":"4","key":"1680_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/acsinfecdis.1c00527","volume":"8","author":"K Samby","year":"2022","unstructured":"Samby K, Besson D, Dutta A, Patra B, Doy A, Glossop P, et al. The pandemic response Box\u2500 accelerating drug discovery efforts after disease outbreaks. ACS Infect Dis. 2022;8(4):713\u201320.","journal-title":"ACS Infect Dis"},{"key":"1680_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040739","author":"RS Celed\u00f3n","year":"2021","unstructured":"Celed\u00f3n RS, D\u00edaz LB. Natural pigments of bacterial origin and their possible biomedical applications. Microorganisms. 2021. https:\/\/doi.org\/10.3390\/microorganisms9040739.","journal-title":"Microorganisms"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13205-018-1227-x","volume":"8","author":"M Numan","year":"2018","unstructured":"Numan M, Bashir S, Mumtaz R, Tayyab S, Rehman NU, Khan AL, et al. Therapeutic applications of bacterial pigments: a review of current status and future opportunities. 3 Biotech. 2018;8:1\u201315.","journal-title":"3 Biotech"},{"issue":"4","key":"1680_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/pre.12141","volume":"64","author":"G Selvaraj","year":"2016","unstructured":"Selvaraj G, Kaliamurthi S, Cakmak ZE, Cakmak T. Computational screening of dipeptidyl peptidase IV inhibitors from micoroalgal metabolites by pharmacophore modeling and molecular docking. Phycol Res. 2016;64(4):291\u20139.","journal-title":"Phycol Res"},{"issue":"1","key":"1680_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12866-024-03697-4","volume":"25","author":"GHE Sayed","year":"2025","unstructured":"Sayed GHE, Fadel M, Fouad R, Ahmed HM, Hamed AA. Improving natural red pigment production by Streptomyces phaeolivaceus strain GH27 for functionalization of textiles with in silico ADME prediction. BMC Microbiol. 2025;25(1):19.","journal-title":"BMC Microbiol"},{"issue":"7","key":"1680_CR21","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1007\/s12010-023-04358-4","volume":"195","author":"M Rudrappa","year":"2023","unstructured":"Rudrappa M, Nayaka S, Kumar RS. In silico molecular docking approach of melanin against melanoma causing MITF proteins and anticancer, oxidation-reduction, photoprotection, and drug-binding affinity properties of extracted melanin from Streptomyces sp. strain MR28. Appl Biochem Biotechnol. 2023;195(7):4368\u201386.","journal-title":"Appl Biochem Biotechnol"},{"issue":"11\u201312","key":"1680_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ansa.202400039","volume":"5","author":"T Rahman","year":"2024","unstructured":"Rahman T, Bappi MSH, Hossain TJ. Prodigiosin demonstrates promising antiviral activity against Dengue virus and Zika virus in in-silico study. Anal Sci Adv. 2024;5(11\u201312):e202400039.","journal-title":"Anal Sci Adv"},{"issue":"1","key":"1680_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12866-024-03634-5","volume":"24","author":"MA Hamada","year":"2024","unstructured":"Hamada MA, Mohamed ET. Characterization of Serratia marcescens (OK482790)\u2019 prodigiosin along with in vitro and in silico validation for its medicinal bioactivities. BMC Microbiol. 2024;24(1):495.","journal-title":"BMC Microbiol"},{"issue":"3","key":"1680_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12291-022-01056-6","volume":"38","author":"N Sahu","year":"2023","unstructured":"Sahu N, Mishra S, Kesheri M, Kanchan S, Sinha RP. Identification of cyanobacteria-based natural inhibitors against SARS-CoV-2 druggable target ACE2 using molecular docking study, ADME and toxicity analysis. Indian J Clin Biochem. 2023;38(3):361\u201373.","journal-title":"Indian J Clin Biochem"},{"issue":"1","key":"1680_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-021-02694-4","volume":"79","author":"\u015e \u00c7obano\u011flu","year":"2021","unstructured":"\u00c7obano\u011flu \u015e, Yaz\u0131c\u0131 A. Isolation, characterization, and antibiofilm activity of pigments synthesized by Rhodococcus sp. SC1. Curr Microbiol. 2021;79(1):15.","journal-title":"Curr Microbiol"},{"issue":"1","key":"1680_CR26","doi-asserted-by":"publisher","first-page":"3962301","DOI":"10.1155\/2022\/3962301","volume":"2022","author":"Z Kazi","year":"2022","unstructured":"Kazi Z, Hungund BS, Yaradoddi JS, Banapurmath N, Yusuf AA, Kishore KL, et al. Production, characterization, and antimicrobial activity of pigment from streptomyces species. J Nanomater. 2022;2022(1):3962301.","journal-title":"J Nanomater"},{"issue":"1","key":"1680_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13104-024-06834-4","volume":"17","author":"SB Chaturwedi","year":"2024","unstructured":"Chaturwedi SB, Mainali S, Chaudhary R. Antibacterial activity of pigment extracted from bacteria isolated from soil samples. BMC Res Notes. 2024;17(1):169.","journal-title":"BMC Res Notes"},{"issue":"1","key":"1680_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12934-024-02438-6","volume":"23","author":"MA Marey","year":"2024","unstructured":"Marey MA, Abozahra R, El-Nikhely NA, Kamal MF, Abdelhamid SM, El-Kholy MA. Transforming microbial pigment into therapeutic revelation: extraction and characterization of pyocyanin from Pseudomonas aeruginosa and its therapeutic potential as an antibacterial and anticancer agent. Microb Cell Fact. 2024;23(1):174.","journal-title":"Microb Cell Fact"},{"issue":"1","key":"1680_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12934-023-02276-y","volume":"23","author":"NA El-Zawawy","year":"2024","unstructured":"El-Zawawy NA, Kenawy E-R, Ahmed S, El-Sapagh S. Bioproduction and optimization of newly characterized melanin pigment from Streptomyces djakartensis NSS-3 with its anticancer, antimicrobial, and radioprotective properties. Microb Cell Fact. 2024;23(1):23.","journal-title":"Microb Cell Fact"},{"issue":"7","key":"1680_CR30","first-page":"2817","volume":"22","author":"A Arifiyanto","year":"2021","unstructured":"Arifiyanto A, Setyaningrum E, Nukmal N, Aeny TN. In vitro antimicrobial and antimalarial screening of a crude extract of Streptomyces sp. AB8 isolated from Lapindo Mud Volcano Area, Sidoarjo Indonesia. Biodiversitas J Biol Diver. 2021;22(7):2817\u201323.","journal-title":"Biodiversitas J Biol Diver"},{"key":"1680_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2021.102432","volume":"85","author":"D Waluyo","year":"2021","unstructured":"Waluyo D, Prabandari EE, Pramisandi A, Hidayati DN, Chrisnayanti E, Puspitasari DJ, et al. Exploring natural microbial resources for the discovery of anti-malarial compounds. Parasitol Int. 2021;85:102432.","journal-title":"Parasitol Int"},{"issue":"1","key":"1680_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-022-00452-y","volume":"20","author":"NA Hemeda","year":"2022","unstructured":"Hemeda NA, Hegazy GE, Abdelgalil SA, Soliman NA, Abdel-Meguid DI, El-Assar SA. Maximization of red pigment production from Streptomyces sp. LS1 structure elucidation and application as antimicrobial\/antifouling against human pathogens and marine microbes. J Genet Eng Biotechnol. 2022;20(1):168.","journal-title":"J Genet Eng Biotechnol"},{"issue":"2","key":"1680_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1\u20132:19\u201325.","journal-title":"SoftwareX"},{"issue":"10","key":"1680_CR35","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30(10):1545\u2013614.","journal-title":"J Comput Chem"},{"key":"1680_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2020.107325","volume":"88","author":"A Jim\u00e9nez-Alberto","year":"2020","unstructured":"Jim\u00e9nez-Alberto A, Ribas-Aparicio RM, Aparicio-Ozores G, Castel\u00e1n-Vega JA. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. Comput Biol Chem. 2020;88:107325.","journal-title":"Comput Biol Chem"},{"issue":"11","key":"1680_CR37","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem. 2008;29(11):1859\u201365.","journal-title":"J Comput Chem"},{"issue":"3","key":"1680_CR38","doi-asserted-by":"publisher","first-page":"641a","DOI":"10.1016\/j.bpj.2015.11.3431","volume":"110","author":"J Lee","year":"2016","unstructured":"Lee J, Cheng X, Jo S, MacKerell AD, Klauda JB, Im W. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field. Biophys J. 2016;110(3):641a.","journal-title":"Biophys J"},{"key":"1680_CR39","doi-asserted-by":"publisher","DOI":"10.1063\/1.2408420","author":"G Bussi","year":"2007","unstructured":"Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys. 2007. https:\/\/doi.org\/10.1063\/1.2408420.","journal-title":"J Chem Phys"},{"issue":"12","key":"1680_CR40","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess B, Bekker H, Berendsen HJ, Fraaije JG. LINCS: a linear constraint solver for molecular simulations. J Comput Chem. 1997;18(12):1463\u201372.","journal-title":"J Comput Chem"},{"issue":"19","key":"1680_CR41","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys. 1995;103(19):8577\u201393.","journal-title":"J Chem Phys"},{"issue":"1","key":"1680_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33\u20138.","journal-title":"J Mol Graph"},{"issue":"11","key":"1680_CR43","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1021\/acs.jcim.8b00512","volume":"58","author":"T Tubiana","year":"2018","unstructured":"Tubiana T, Carvaillo J-C, Boulard Y, Bressanelli S. TTclust: a versatile molecular simulation trajectory clustering program with graphical summaries. J Chem Inf Model. 2018;58(11):2178\u201382.","journal-title":"J Chem Inf Model"},{"issue":"W1","key":"1680_CR44","doi-asserted-by":"publisher","first-page":"W443","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"S Salentin","year":"2015","unstructured":"Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein\u2013ligand interaction profiler. Nucleic Acids Res. 2015;43(W1):W443\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"1680_CR45","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E. Gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput. 2021;17(10):6281\u201391.","journal-title":"J Chem Theory Comput"},{"issue":"9","key":"1680_CR46","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller III","year":"2012","unstructured":"Miller III BR, McGee TD, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA. py: an efficient program for end-state free energy calculations. J Chem Theory computat. 2012;8(9):3314\u201321.","journal-title":"J Chem Theory computat"},{"issue":"5","key":"1680_CR47","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1021\/acschemneuro.7b00490","volume":"9","author":"W Xue","year":"2018","unstructured":"Xue W, Yang F, Wang P, Zheng G, Chen Y, Yao X, et al. What contributes to serotonin\u2013norepinephrine reuptake inhibitors\u2019 dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation. ACS Chem Neurosci. 2018;9(5):1128\u201340.","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"1680_CR48","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/17460441.2021.1942836","volume":"16","author":"T Tuccinardi","year":"2021","unstructured":"Tuccinardi T. What is the current value of MM\/PBSA and MM\/GBSA methods in drug discovery? Expert Opin Drug Discov. 2021;16(11):1233\u20137.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"1680_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13321-021-00548-6","volume":"13","author":"C Bouysset","year":"2021","unstructured":"Bouysset C, Fiorucci S. Prolif: a library to encode molecular interactions as fingerprints. J Cheminform. 2021;13(1):72.","journal-title":"J Cheminform"},{"issue":"6","key":"1680_CR50","first-page":"417","volume":"4","author":"PAR El Feghali","year":"2018","unstructured":"El Feghali PAR, Nawas T. Extraction and purification of pyocyanin: a simpler and more reliable method. MOJ Toxicol. 2018;4(6):417\u201322.","journal-title":"MOJ Toxicol"},{"issue":"5","key":"1680_CR51","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s44211-024-00531-9","volume":"40","author":"F Farouk","year":"2024","unstructured":"Farouk F, Shebl RI. LC\u2013MS\/MS determination of pyocyanin\u2013N-acetyl cysteine adduct: application for understanding Pseudomonas aeruginosa virulence factor neutralization. Anal Sci. 2024;40(5):891\u2013905.","journal-title":"Anal Sci"},{"issue":"6","key":"1680_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot095505","volume":"2018","author":"P Kumar","year":"2018","unstructured":"Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018;2018(6):pdb. prot095505.","journal-title":"Cold Spring Harb Protoc"},{"issue":"1","key":"1680_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","volume":"36","author":"C Lei","year":"2021","unstructured":"Lei C, Yang J, Hu J, Sun X. On the calculation of TCID50 for quantitation of virus infectivity. Virol Sin. 2021;36(1):141\u20134.","journal-title":"Virol Sin"},{"key":"1680_CR54","doi-asserted-by":"crossref","unstructured":"Baid K, Chiok KR, Banerjee A.\u00a0Median tissue culture infectious dose 50 (TCID50) assay to determine infectivity of cytopathic viruses. In Intracellular Pathogens: Methods and Protocols, Thakur, A., Ed. Springer US: New York, NY, 2024; pp 117\u2013123.","DOI":"10.1007\/978-1-0716-3890-3_8"},{"key":"1680_CR55","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2217\/fvl-2023-0119","volume":"18","author":"F Farouk","year":"2023","unstructured":"Farouk F, Zarka MA, Al-Sawahli MM, Hassan A, Mohamed AF, Ibrahim IM, et al. Rosmarinic acid inhibits Rift Valley fever virus: in vitro, computational and analytical studies. Futur Virol. 2023;18:1001\u201319.","journal-title":"Futur Virol"},{"issue":"2","key":"1680_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/17460441.2012.648612","volume":"7","author":"WP Walters","year":"2012","unstructured":"Walters WP. Going further than Lipinski\u2019s rule in drug design. Expert Opin Drug Discov. 2012;7(2):99\u2013107.","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"1680_CR57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/encyclopedia3020035","volume":"3","author":"S Kralj","year":"2023","unstructured":"Kralj S, Juki\u010d M, Bren U. Molecular filters in medicinal chemistry. Encyclopedia. 2023;3(2):501\u201311.","journal-title":"Encyclopedia"},{"issue":"3","key":"1680_CR58","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge I. Selection criteria for drug-like compounds. Med Res Rev. 2003;23(3):302\u201321.","journal-title":"Med Res Rev"},{"issue":"5","key":"1680_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010231","volume":"18","author":"NR Hum","year":"2022","unstructured":"Hum NR, Bourguet FA, Sebastian A, Lam D, Phillips AM, Sanchez KR, et al. MAVS mediates a protective immune response in the brain to Rift Valley fever virus. PLoS Pathog. 2022;18(5):e1010231.","journal-title":"PLoS Pathog"},{"key":"1680_CR60","unstructured":"Farouk F, Shebl RI, Azzazy HM. In antiviral potential of microbial pigments: the case of pyocyanin, biochemistry and cell biology, Canadian science publishing 65 Auriga Dr, SUITE 203, OTTAWA, ON K2E 7W6, CANADA: 2023."},{"key":"1680_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ph15060659","author":"MA Alamri","year":"2022","unstructured":"Alamri MA, Mirza MU, Adeel MM, Ashfaq UA, Tahir Ul Qamar M, Shahid F, et al. Structural elucidation of Rift Valley fever virus L protein towards the discovery of its potential inhibitors. Pharmaceuticals. 2022. https:\/\/doi.org\/10.3390\/ph15060659.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1680_CR62","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41598-023-27954-0","volume":"13","author":"A Hegazy","year":"2023","unstructured":"Hegazy A, Mahmoud SH, Elshaier YAMM, Shama NMA, Nasr NF, Ali MA, et al. Antiviral activities of plant-derived indole and \u03b2-carboline alkaloids against human and avian influenza viruses. Sci Rep. 2023;13(1):1612.","journal-title":"Sci Rep"},{"key":"1680_CR63","doi-asserted-by":"crossref","unstructured":"Muralitharan, I.; Sahoo, A. K.; Augusthian, P. D.; Samal, A., Computational prediction of phytochemical inhibitors against the cap-binding domain of Rift Valley fever virus. Molecular Diversity 2023, 1\u201314.","DOI":"10.21203\/rs.3.rs-2902753\/v1"},{"key":"1680_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/v8050149","author":"I Phoenix","year":"2016","unstructured":"Phoenix I, Nishiyama S, Lokugamage N, Hill TE, Huante MB, Slack OA, et al. N-glycans on the Rift Valley fever virus envelope glycoproteins Gn and Gc redundantly support viral infection via DC-SIGN. Viruses. 2016. https:\/\/doi.org\/10.3390\/v8050149.","journal-title":"Viruses"},{"issue":"1","key":"1680_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00769-w","volume":"8","author":"C Alkan","year":"2023","unstructured":"Alkan C, Jurado-Cobena E, Ikegami T. Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates. NPJ Vaccines. 2023;8(1):171.","journal-title":"NPJ Vaccines"},{"issue":"6","key":"1680_CR66","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1021\/acsmedchemlett.2c00067","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Dan\u011bk O, Makarov D, R\u00e1dl S, Kim D, Ledvinka J, et al. Drug-like inhibitors of DC-SIGN based on a quinolone scaffold. ACS Med Chem Lett. 2022;13(6):935\u201342.","journal-title":"ACS Med Chem Lett"},{"issue":"42","key":"1680_CR67","doi-asserted-by":"publisher","first-page":"12780","DOI":"10.1021\/ja072944v","volume":"129","author":"MJ Borrok","year":"2007","unstructured":"Borrok MJ, Kiessling LL. Non-carbohydrate inhibitors of the lectin DC-SIGN. J Am Chem Soc. 2007;129(42):12780\u20135.","journal-title":"J Am Chem Soc"},{"issue":"3","key":"1680_CR68","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/molecules27031112","volume":"27","author":"RW Huigens","year":"2022","unstructured":"Huigens RW, Brummel BR, Tenneti S, Garrison AT, Xiao T. Pyrazine and phenazine heterocycles: platforms for total synthesis and drug discovery. Molecules. 2022;27(3):1112.","journal-title":"Molecules"},{"issue":"5","key":"1680_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/v8050149","volume":"8","author":"I Phoenix","year":"2016","unstructured":"Phoenix I, Nishiyama S, Lokugamage N, Hill TE, Huante MB, Slack OAL, et al. N-glycans on the Rift Valley fever virus envelope glycoproteins Gn and Gc redundantly support viral infection via DC-SIGN. Viruses. 2016;8(5):149.","journal-title":"Viruses"},{"issue":"5","key":"1680_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007829","volume":"15","author":"N Gogrefe","year":"2019","unstructured":"Gogrefe N, Reindl S, G\u00fcnther S, Rosenthal M. Structure of a functional cap-binding domain in Rift Valley fever virus L protein. PLoS Pathog. 2019;15(5):e1007829.","journal-title":"PLoS Pathog"},{"issue":"11","key":"1680_CR71","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.1021\/acsomega.8b01607","volume":"3","author":"S Sheet","year":"2018","unstructured":"Sheet S, Vinothkannan M, Balasubramaniam S, Subramaniyan SA, Acharya S, Lee YS. Highly flexible electrospun hybrid (polyurethane\/dextran\/pyocyanin) membrane for antibacterial activity via generation of oxidative stress. ACS Omega. 2018;3(11):14551\u201361.","journal-title":"ACS Omega"},{"issue":"1","key":"1680_CR72","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1021\/acs.iecr.4c04206","volume":"64","author":"J Honselmann genannt Humme","year":"2025","unstructured":"Honselmann genannt Humme J, Ossowicz-Rupniewska P, Jurkiewicz M, Gano M, Dubrowska K, Augustyniak A, et al. The comparison of typical organic solvents and ionic liquid for more environmentally and user-friendly pyocyanin extraction. Ind Eng Chem Res. 2025;64(1):781\u20137.","journal-title":"Ind Eng Chem Res"},{"key":"1680_CR73","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11274-013-1552-5","volume":"30","author":"S Jayaseelan","year":"2014","unstructured":"Jayaseelan S, Ramaswamy D, Dharmaraj S. Pyocyanin: production, applications, challenges and new insights. World J Microbiol Biotechnol. 2014;30:1159\u201368.","journal-title":"World J Microbiol Biotechnol"},{"issue":"1","key":"1680_CR74","first-page":"36","volume":"8","author":"MZ El-Fouly","year":"2015","unstructured":"El-Fouly MZ, Sharaf AM, Shahin AAM, El-Bialy HA, Omara AMA. Biosynthesis of pyocyanin pigment by Pseudomonas aeruginosa. J Radiat Res Appl Sci. 2015;8(1):36\u201348.","journal-title":"J Radiat Res Appl Sci"},{"issue":"3","key":"1680_CR75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11274-024-03889-0","volume":"40","author":"SB Mudaliar","year":"2024","unstructured":"Mudaliar SB, Bharath Prasad AS. A biomedical perspective of pyocyanin from Pseudomonas aeruginosa: its applications and challenges. World J Microbiol Biotechnol. 2024;40(3):90.","journal-title":"World J Microbiol Biotechnol"},{"issue":"15","key":"1680_CR76","doi-asserted-by":"publisher","first-page":"8451","DOI":"10.1128\/JVI.03382-12","volume":"87","author":"R Mudhasani","year":"2013","unstructured":"Mudhasani R, Tran Julie P, Retterer C, Radoshitzky Sheli R, Kota Krishna P, Altamura Louis A, et al. IFITM-2 and IFITM-3 but Not IFITM-1 Restrict Rift Valley Fever Virus. J Virol. 2013;87(15):8451\u201364.","journal-title":"J Virol"},{"key":"1680_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075","volume":"9","author":"FD Makurvet","year":"2021","unstructured":"Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov. 2021;9:100075.","journal-title":"Med Drug Discov"},{"issue":"12","key":"1680_CR78","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1128\/JCM.39.12.4456-4461.2001","volume":"39","author":"S Garcia","year":"2001","unstructured":"Garcia S, Crance Jean M, Billecocq A, Peinnequin A, Jouan A, Bouloy M, et al. Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds. J Clin Microbiol. 2001;39(12):4456\u201361.","journal-title":"J Clin Microbiol"},{"issue":"12","key":"1680_CR79","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1128\/AAC.03595-14","volume":"58","author":"M Ellenbecker","year":"2014","unstructured":"Ellenbecker M, Lanchy J-M, Lodmell JS. Inhibition of rift valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin. Antimicrob Agents Chemother. 2014;58(12):7405\u201315.","journal-title":"Antimicrob Agents Chemother"},{"key":"1680_CR80","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","volume":"104","author":"D Scharton","year":"2014","unstructured":"Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antivir Res. 2014;104:84\u201392.","journal-title":"Antivir Res"},{"key":"1680_CR81","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00669-19","author":"B Borrego","year":"2019","unstructured":"Borrego B, de \u00c1vila Ana I, Domingo E, Brun A. Lethal mutagenesis of rift valley fever virus induced by favipiravir. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.00669-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1680_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13267-1","volume":"12","author":"I Fatima","year":"2022","unstructured":"Fatima I, Ahmad S, Alamri MA, Mirza MU, Tahir ul Qamar M, Rehman A, et al. Discovery of Rift Valley fever virus natural pan-inhibitors by targeting its multiple key proteins through computational approaches. Sci Rep. 2022;12(1):9260.","journal-title":"Sci Rep"},{"key":"1680_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00676","volume":"6","author":"A Benedict","year":"2015","unstructured":"Benedict A, Bansal N, Senina S, Hooper I, Lundberg L, de la Fuente C, et al. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front Microbiol. 2015;6:676.","journal-title":"Front Microbiol"},{"issue":"8","key":"1680_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003095","volume":"8","author":"R Mudhasani","year":"2014","unstructured":"Mudhasani R, Kota KP, Retterer C, Tran JP, Whitehouse CA, Bavari S. High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses. PLoS Negl Trop Dis. 2014;8(8):e3095.","journal-title":"PLoS Negl Trop Dis"},{"key":"1680_CR85","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.vetmic.2019.01.027","volume":"230","author":"Y Lang","year":"2019","unstructured":"Lang Y, Li Y, Jasperson D, Henningson J, Lee J, Ma J, et al. Identification and evaluation of antivirals for Rift Valley fever virus. Vet Microbiol. 2019;230:110\u20136.","journal-title":"Vet Microbiol"},{"issue":"20","key":"1680_CR86","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1056\/NEJMp2308666","volume":"389","author":"N Wandera","year":"2023","unstructured":"Wandera N, Olds P, Muhindo R, Ivers L. Rift valley fever \u2014 the need for an integrated response. N Engl J Med. 2023;389(20):1829\u201332.","journal-title":"N Engl J Med"},{"key":"1680_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ipha.2024.01.010","author":"M Roney","year":"2024","unstructured":"Roney M, Aluwi MFFM. The importance of in-silico studies in drug discovery. Intelligent Pharmacy. 2024. https:\/\/doi.org\/10.1016\/j.ipha.2024.01.010.","journal-title":"Intelligent Pharmacy"},{"key":"1680_CR88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ymben.2013.02.002","volume":"17","author":"J Zhao","year":"2013","unstructured":"Zhao J, Li Q, Sun T, Zhu X, Xu H, Tang J, et al. Engineering central metabolic modules of Escherichia coli for improving \u03b2-carotene production. Metab Eng. 2013;17:42\u201350.","journal-title":"Metab Eng"},{"key":"1680_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11030614","author":"H Agarwal","year":"2023","unstructured":"Agarwal H, Bajpai S, Mishra A, Kohli I, Varma A, Fouillaud M, et al. Bacterial pigments and their multifaceted roles in contemporary biotechnology and pharmacological applications. Microorganisms. 2023. https:\/\/doi.org\/10.3390\/microorganisms11030614.","journal-title":"Microorganisms"},{"issue":"42","key":"1680_CR90","doi-asserted-by":"publisher","first-page":"17465","DOI":"10.1021\/jacs.1c06778","volume":"143","author":"J Cramer","year":"2021","unstructured":"Cramer J, Lakkaichi A, Aliu B, Jakob RP, Klein S, Cattaneo I, et al. Sweet drugs for bad bugs: a glycomimetic strategy against the DC-SIGN-mediated dissemination of SARS-CoV-2. J Am Chem Soc. 2021;143(42):17465\u201378.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1680_CR91","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41467-017-02789-2","volume":"9","author":"S Halldorsson","year":"2018","unstructured":"Halldorsson S, Li S, Li M, Harlos K, Bowden TA, Huiskonen JT. Shielding and activation of a viral membrane fusion protein. Nat Commun. 2018;9(1):349.","journal-title":"Nat Commun"},{"issue":"5","key":"1680_CR92","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1073\/pnas.1217780110","volume":"110","author":"M Dessau","year":"2013","unstructured":"Dessau M, Modis Y. Crystal structure of glycoprotein C from Rift Valley fever virus. Proc Natl Acad Sci. 2013;110(5):1696\u2013701.","journal-title":"Proc Natl Acad Sci"},{"issue":"26","key":"1680_CR93","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1073\/pnas.1001760107","volume":"107","author":"DD Raymond","year":"2010","unstructured":"Raymond DD, Piper ME, Gerrard SR, Smith JL. Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc Natl Acad Sci U S A. 2010;107(26):11769\u201374.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01680-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:09:53Z","timestamp":1773320993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13065-025-01680-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01680-2","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}